For hypoglycemic drug therapy, it is important to reduce hypoglycemia, to use sodium glucose cotransporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 (GLP‐1) receptor agonists, taking into account the benefits for cardiovascular disease and the risk of adverse effects, and to simplify treatment to address poor adherence. The gene discussed is GLP1R; the disease is cardiovascular disorder.